Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
InterveXion Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
InterveXion Therapeutics

InterveXion Therapeutics

InterveXion, a US biopharmaceutical firm, develops novel treatments for addiction disorders, including a FDA Fast Track Designated methamphetamine antibody.

HQ
Little Rock, AR, US
Founded
2004
Overview
Compare
Fundraising
Employees
Website

InterveXion Therapeutics, founded in Little Rock, United States, is a privately-held clinical-stage biopharmaceutical company focused on developing innovative treatments for addiction disorders. Their core mission is to address the unmet medical needs of individuals suffering from substance use disorders through advanced biotechnological solutions. The company's lead product candidate, IXT-m200, is a monoclonal antibody targeting methamphetamine, designed to redirect the drug away from the central nervous system. This product has received Fast Track Designation from the US FDA and is currently in a Phase 2 proof-of-concept study.

Notable figures affiliated with InterveXion include a team of experienced scientists and clinicians dedicated to addiction medicine. The company has garnered significant attention and investment due to its groundbreaking approach to treating methamphetamine addiction. Key achievements include the successful enrollment of patients in the OUTLAST Phase study and positive safety data from their Phase study of Devextinetug for methamphetamine overdose. InterveXion's work has the potential to significantly impact public health by providing effective treatments for addiction, thereby improving patient outcomes and reducing the societal burden of substance abuse.

InterveXion Therapeutics - Quick Facts

When was InterveXion Therapeutics founded?

InterveXion Therapeutics was founded in 2004.

Where is InterveXion Therapeutics' headquarters located?

InterveXion Therapeutics' headquarters is located in Little Rock, AR, US.

When was InterveXion Therapeutics' last funding round?

InterveXion Therapeutics' most recent funding round was for $13.8M (USD) in November 2021.

How much has InterveXion Therapeutics raised to-date?

As of Nov 1, 2021, InterveXion Therapeutics has raised a total of $52.8M (USD).

How many employees does InterveXion Therapeutics have?

InterveXion Therapeutics has 75 employees as of Feb 4, 2024.

InterveXion Therapeutics - Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biopharmaceuticals
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified